LY3971297 for Heart Failure

Not yet recruiting at 2 trial locations

Overseen By Physicians interested in becoming principal investigators please contact

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Eli Lilly and Company

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 2 months and will include 1 inpatient visit lasting approximately 4 days and 5 outpatient visits.

Who Is on the Research Team?

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

Inclusion Criteria

Have a body mass index within the range of 18.5 to 40 kg/m²

I have chronic heart failure with moderate symptoms and have been on treatment for 6 months.

I was hospitalized for heart failure between 30 days and 12 months ago.

Exclusion Criteria

I have heart failure and am listed for a transplant or recently had certain heart devices placed.

Have resting heart rate >90 bpm at screening

For US sites: have donated blood of more than 500 mL within the previous 90 days of screening or intend to donate blood during the course of the study

What Are the Treatments Tested in This Trial?

Interventions

• LY3971297

How Is the Trial Designed?

Group I: LY3971297 Part B Experimental Treatment 1 Intervention

LY3971297 administered SC or IV

Group II: LY3971297 Part A Cohort 5 Experimental Treatment 1 Intervention

LY3971297 administered intravenously (IV)

Group III: LY3971297 Part A Cohort 4 Experimental Treatment 1 Intervention

LY3971297 administered SC

Group IV: LY3971297 Part A Cohort 3 Experimental Treatment 1 Intervention

LY3971297 administered SC

Group V: LY3971297 Part A Cohort 2 Experimental Treatment 1 Intervention

LY3971297 administered SC

Group VI: LY3971297 Part A Cohort 1 Experimental Treatment 1 Intervention

LY3971297 administered subcutaneously (SC)

Group VII: Placebo Part A Cohort 2 Placebo Group 1 Intervention

Placebo administered SC

Group VIII: Placebo Part A Cohort 4 Placebo Group 1 Intervention

Placebo administered SC

Group IX: Placebo Part B Placebo Group 1 Intervention

Placebo administered SC or IV

Group X: Placebo Part A Cohort 3 Placebo Group 1 Intervention

Placebo administered SC

Group XI: Placebo Part A Cohort 1 Placebo Group 1 Intervention

Placebo administered SC

Group XII: Placebo Part A Cohort 5 Placebo Group 1 Intervention

Placebo administered IV

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University